Oligomerix: Tau tapping

The primary focus of most drug discovery in Alzheimer's disease has been on the large intraneuronal plaques of beta amyloid or the neurofibrillary tangles of tau protein. Oligomerix Inc. is working on microtubule-associated protein tau (MAPT)(tau)(FTDP-17), but a step earlier, before the tangles form. The company believes its work may result in disease-modifying therapeutics, as well as assays for early diagnosis.

In a normal state, tau protein stabilizes axonal microtubules necessary

Read the full 700 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE